|
MechanismM3 receptor antagonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date21 May 2015 |
A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control
100 Clinical Results associated with Boehringer Ingelheim Korea Ltd.
0 Patents (Medical) associated with Boehringer Ingelheim Korea Ltd.
100 Deals associated with Boehringer Ingelheim Korea Ltd.
100 Translational Medicine associated with Boehringer Ingelheim Korea Ltd.